First Nebraska Trust Co Acquires New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• First Nebraska Trust Co. acquired 3,006 Thermo Fisher shares worth approximately $1.51 million in the second quarter, while institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 versus the $5.71 consensus estimate and revenue of $11.99 billion, up 10.5% year over year.
• Shares opened at $629.02, near their 52-week high, while insiders sold 63,493 shares worth $37.7 million during the last quarter. Analysts maintain a “Moderate Buy” consensus with an average price target of $619.41.

First Nebraska Trust Co acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,006 shares of the medical research company's stock, valued at approximately $1,507,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $7,505,000. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. Hudson Value Partners LLC raised its position in shares of Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock worth $8,349,000 after buying an additional 3,317 shares in the last quarter. Xponance LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after acquiring an additional 4,436 shares in the last quarter. Finally, Annex Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 12.6% in the second quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company's stock valued at $12,361,000 after buying an additional 2,756 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 63,493 shares of company stock valued at $37,657,681. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $629.02 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The business's 50-day moving average price is $542.53 and its two-hundred day moving average price is $509.70. The company has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Piper Sandler upped their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a report on Monday, July 27th. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price for the company. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and cut their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source